In Massachusetts, Lilly Asia Ventures, Trustbridge Partners, and Jiangsu Simcere Pharmaceutical gave Veritas Genetics $30 million in Series B funding. Veritas Genetics focuses on genome sequencing and genetic screening tests, mostly related to cancer and reproductive health. Veritas was the first company to offer genetic sequencing for under $1,000, making it a realistic prospect for more people. Mirza Cifric, founder and CEO of Veritas Genetics, told PR Newswire, “With a $999 genome, we are at the tipping point of a transformation in healthcare where the genome is going to be at the center of many decisions we make about our health and quality of life, throughout our lives.” This latest funding will go towards global expansion of operations and hospital and researcher partnerships. They welcomed three new executives to their team to help with the expansion, Tim Smith as Chief Operating Officer, Rodrigo Martinez as Chief Marketing and Design Officer, and Doug Flood as Chief Commercial Officer.
Latest article
Body-based burial: Students imagine urns made from blood and hair
In Slovenia, students at University of Ljubljana have used biobased materials for a variety of design projects, including a biodegradable urn made of blood...
Uttar Pradesh eyes cow poop plastics to boost rural economy
In Uttar Pradesh, a government project is collecting cow dung to convert into usable products such as bioplastics, textiles, and paper.
The Press Trust...
Luxury brand Velvet Eyewear lauds advances in biobased acetate
In California, luxury women’s eyewear brand Velvet Eyewear has unveiled its first biobased eyewear collection.
Crafted from renewable sources like wood pulp and cotton...